摘要：2025年5月12日，上海皓元医药股份有限公司（股票代码：688131，以下简称“皓元医药”）与韩国ADC生物技术公司AbTis Co., Ltd.（以下简称“AbTis”）正式签署战略合作协议（MOU）。
Swipe Left For English News
2025年5月12日，上海皓元医药股份有限公司（股票代码：688131，以下简称“皓元医药”）与韩国ADC生物技术公司AbTis Co., Ltd.（以下简称“AbTis”）正式签署战略合作协议（MOU）。
皓元医药董事长兼总经理郑保富博士（左）
AbTis首席执行官Tae Dong Han博士（右）
AbTis公司旨在通过应用AbTis的定点偶联技术平台AbClick，提高现有ADC的安全性和有效性，从而改善癌症患者的治疗效果。皓元医药将充分发挥其在ADC早期发现到CDMO比较细分专业领域中的专业优势，与AbTis达成深度合作，致力于整合前沿定点偶联技术与全方位ADC研发实力，为客户提供创新高效的解决方案。
AbClick创建了简单、高效、低成本的偶联技术，且能够精准控制半衰期、DAR和连接子-有效载荷稳定性等关键参数，为探索最佳ADC新药提供了可行的方案。而皓元医药拥有一站式ADC研发及GMP生产平台，双方的深入合作将赋能ADC创新药企业，加速推进具有差异化临床优势的创新ADC管线开发。
皓元医药与AbTis公司达成的战略合作包括但不限于定点偶联技术平台AbClick的市场应用。此次战略合作将推动皓元医药进一步深耕ADC领域，双方将充分发挥各自在生物偶联技术与产业化方面的核心优势，通过深度协同创新，加速突破新一代ADC药物的开发进程。这一合作不仅将提升全球ADC产业链的竞争力，更将推动创新疗法早日惠及亟待治疗的患者群体，为人类健康事业创造持久价值。
AbTis
首席执行官Tae Dong Han博士
“
皓元医药作为中国最早研究ADC的公司之一，我们相信凭借其深厚的技术积淀与专业人才优势，与AbClick技术平台的协同融合将持续深化定点偶联技术应用，有力推动突破性ADC疗法的创新进程，为全球患者带来更具临床价值、更安全有效的精准治疗方案，共同开创ADC治疗领域的新纪元。
“
皓元医药
董事长兼总经理郑保富博士
“
我们非常高兴与AbTis达成战略合作，AbTis具有自主知识产权的第三代抗体偶联技术平台AbClick，皓元医药具备服务于海内外ADC药物的研发与生产能力，此次合作将进一步发挥双方在各自领域的优势，助力加速新一代ADC药物和生物偶联药物的研发进程，促进海内外交流融合，早日造福全球患者。
“
关于AbTis
AbTis是一家生物技术公司，拥有专有的第三代接头平台AbClick，该平台能够开发位点选择性抗体偶联疗法，用于靶向递送各种治疗有效载荷。通过AbClick，AbTis建立了一种简单但成本效益高的偶联过程，可以扩展各种形式的生物偶联治疗，如ADC、ARC、DAC等，所有这些都不需要修饰抗体。AbClick还可以精确控制半衰期、DAR和接头有效载荷稳定性等关键参数，这些参数对于设计最佳的生物偶联疗法至关重要。 AbTis已经建立了越来越多的合作关系，以开发一流的治疗候选药物，同时开发自己的临床开发管道。AbTis于2023年被Dong-A ST收购，致力于开发创新疗法，坚定不移地为有需要的患者提供治疗。更多信息，请查询：.kr
关于皓元医药
上海皓元医药股份有限公司（股票代码：688131）成立于2006年，专注于为全球制药和生物医药行业提供小分子、大分子及新分子类型药物发现领域的生命科学试剂的研发，原料药、中间体、起始物料及制剂的药物研发，工艺优化及商业化生产。公司始终将创新作为核心驱动力，以“产品+服务”模式，聚焦差异化发展，致力于打造覆盖药物研发及生产“起始物料 - 中间体 - 原料药 - 制剂”的一体化服务平台，加速赋能全球合作伙伴实现从临床前到商业化生产的全过程，让药物研发更高效，更快上市，更早惠及人类健康。
On May 12, 2025, Shanghai Haoyuan Chemexpress Co., Ltd. (stock code: 688131, hereinafter referred to as "ChemExpress") officially signed a strategic cooperation agreement (MOU) with AbTis Co., Ltd. (hereinafter referred to as "AbTis"), a South Korean ADC biotechnology company.
Dr. Zheng Baofu, Chairman of ChemExpress（left）
Dr. Tae Dong Han, CEO of AbTis（right）
AbTis aims to utilize AbClick, which is AbTis' proprietary site-selective antibody conjugate technology platform, to improve the safety and effectiveness of existing ADCs to enhance the treatment outcomes for cancer patients. ChemExpress will fully leverage its professional advantages from early discovery stage to commercial scale in ADC CDMO in specialized fields, and after establishing the deep cooperation with AbTis, both parties will integrate cutting-edge site-selective antibody conjugate technology and comprehensive ADC research and development capabilities, providing clients with innovative and efficient solutions.
AbClick created a simple, efficient, and low-cost coupling technology that can accurately control the key parameters such as half-life, DAR, the stability of linker-payload, which can provide a feasible solution for exploring the optimal ADC drug. And ChemExpress has a one-stop ADC R&D and GMP production platform. The deep cooperation between the two parties will empower ADC innovative drug companies to accelerate the development of innovative ADC pipelines with differentiated clinical advantages.
The strategic cooperation between ChemExpress and AbTis includes but is not limited to site-selective antibody conjugate technology platform AbClick. This strategic cooperation will promote ChemExpress to further deepen its involvement in the ADC field. Both parties will fully leverage their core advantages in antibody conjugate technology and industrialization, and accelerate the development process of new generation ADC drugs through deep collaborative innovation. This cooperation will not only enhance the competitiveness of the global ADC industry chain, but also promote innovative therapies to benefit patients in urgent need of treatment as early as possible, creating lasting value for human health.
Dr. Tae Dong Han, CEO of AbTis
“
As one of the earliest companies in China began the research in ADC, ChemExpress owns profound technical accumulation and professional talent advantages. The collaborative integration of AbClick technology platforms with ChemExpress will continue to deepen the application of proprietary site-selective antibody conjugate technology, effectively promote the innovation process of ADC therapy breakthrough, bring treatment plans of more clinically valuable, safer and more effective precision to patients worldwide, and jointly create a new era in the field of ADC therapy.
“
Dr. Zheng Baofu, Chairman of ChemExpress
“
We are very pleased to have reached a strategic cooperation with AbTis, which owns the third-generation antibody conjugation technology platform AbClick with independent intellectual property rights. ChemExpress has the ability to serve the research and production of ADC drugs for clients home and abroad. This cooperation will further leverage the advantages of both parties in their respective fields, help accelerate the development process of new generation ADC drugs and bioconjugate drugs, promote communication and integration at home and abroad, and benefit global patients as early as possible.
“
About AbTi
AbTis is a biotechnology company with a proprietary 3rd generation linker platform, AbClick, which enables the development of site-selective antibody conjugate therapies for the targeted delivery of diverse therapeutic payloads. Through AbClick, AbTis has established a simple yet cost-efficient conjugation process that empowers the expansion of diverse forms of bioconjugate treatments, such as ADC, ARC, DAC, and others, all without modifying the antibody. AbClick also allows for precise control over key parameters such as half-life, DAR, and linker-payload stability, which are all essential for designing optimal bioconjugate therapies. AbTis has forged growing number of collaborations to develop best-in-class therapeutic candidates while developing its own pipelines for clinical developments. Acquired by Dong-A ST in 2023, AbTis strives to develop innovative therapies with an unwavering drive to provide therapies to patients in need. For more information, please refer to .kr
About ChemExpress
Founded in 2006, Shanghai Haoyuan Chemexpress Co., Ltd. ("ChemExpress") specializes in offering CRO&CDMO services for pharmaceutical and biotech companies, focusing on small molecules, antibodies and new modalities such as ADCs\XDCs, peptides and PROTACs. Our comprehensive platform is engaged in the research and development, manufacturing and supply of regulatory starting materials, novel building blocks, intermediates, reference compounds, APIs and drug products. We support our clients' projects from early drug discovery, process development to commercialization.
来源：动态宝